Drugs

Papers
(The H4-Index of Drugs is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Acknowledgement to Referees497
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”472
Targeting DNA Damage Response Deficiency in Thoracic Cancers288
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema254
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression247
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments224
Eftrenonacog Alfa: A Review in Haemophilia B196
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using167
Teclistamab: First Approval164
Aprocitentan: First Approval156
New Therapies on the Horizon for Primary Biliary Cholangitis146
Senaparib: First Approval144
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences142
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments139
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms128
Vorasidenib: First Approval125
Spesolimab for the Treatment of Generalized Pustular Psoriasis124
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,108
Epcoritamab: First Approval103
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations103
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial102
Repotrectinib: First Approval101
Drugs in Development to Manage Acute Pain93
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure91
Lenacapavir: First Approval91
Tolebrutinib: First Approval90
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms88
Ivarmacitinib Sulfate: First Approval87
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer85
Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses84
Danicopan: First Approval82
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies82
Cosibelimab: First Approval82
Androgenetic Alopecia: Therapy Update79
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine79
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?78
Acoltremon: First Approval76
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?76
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection70
Cancer Pain Treatment Strategies in Patients with Cancer69
Mazdutide: First Approval68
Sibeprenlimab: First Approval68
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids67
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?66
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification66
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema65
Mosunetuzumab: First Approval64
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?63
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough63
Pozelimab: First Approval62
Tovorafenib: First Approval59
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes58
Correction to: Tapinarof Cream 1%: First Approval58
Pixavir Marboxil: First Approval57
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options57
Managing Burning Mouth Syndrome: Current and Future Directions57
The Place of Cannabinoids in the Treatment of Gynecological Pain57
0.081524133682251